title: Interferon treatment in patients with hypereosinophilia.
abstract: Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition--and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia.
authors.affiliation: Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ole.weis.bjerrum@rh.regionh.dk
authors.forename: Ole Weis
authors.initials: OW
authors.lastname: Bjerrum
mesh_terms: D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D019891:Leukopoiesis / Q000187:drug effects
chemical_list: D007155:Immunologic Factors; D016898:Interferon-alpha